Stock 4174 OBI PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages OBI Pharma, Inc.

Equities

4174

TW0004174008

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-06-02 pm EDT 		5-day change 1st Jan Change
58.7 TWD 0.00% Intraday chart for OBI Pharma, Inc. +0.17% -15.42%
May. 30 OBI Pharma, Inc. Files the Application of Phase I/II human clinical trial for OBI-992 TROP2 ADC to TFDA CI
May. 15 OBI Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
OBI Pharma, Inc. Files the Application of Phase I/II human clinical trial for OBI-992 TROP2 ADC to TFDA
OBI Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Obi Pharma, Inc. Announces the Termination of License Agreement with Odeon for the Rights of Obi-999 and Obi-833 in China, Hong Kong and Macau
OBI Pharma, Inc. Announces OBIGEN TFDA Clearance of IND Application for A Phase II Human Clinical Trial
OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform
Obi Pharma, Inc. Announces the Termination of Obi-3424-001 Trial While Continuing the Collaboration Of obi-3424 with Partners
OBI Pharma, Inc. Announces Adagloxad Simolenin (OBI-822) Receives Positive 1st Interim Analysis Recommendation, Recommending the Continues of the Phase III TNBC Trial
Biosion's Partner OBI Pharma Announces FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
OBI Pharma, Inc. Announces OBI-992 TROP2 ADC Has Been Granted by US FDA to Proceed to Phase I/II Human Clinical Trial
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
OBI Pharma, Inc. Announces Resignation of Yun Yen as Chairperson and Director, Effective December 29, 2023
Obi Pharma, Inc. Files the Application of Phase I/II Human Clinical Trial for OBI-992 TROP2 ADC to US FDA
OBI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
OBI Pharma, Inc. Announces Head Office Address Change
OBI Pharma, Inc. Announces Internal Audit Officer Changes
OBI Pharma, Inc. Announces CFO Changes
OBI Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4174 Stock
  4. News OBI Pharma, Inc.
  5. Other languages